Chisato Kamimaki
YOU?
Author Swipe
View article: Investigating EMT-mediated resistance to EGFR tyrosine kinase inhibitors in NSCLC using innovative organoid models
Investigating EMT-mediated resistance to EGFR tyrosine kinase inhibitors in NSCLC using innovative organoid models Open
Background Epithelial-mesenchymal transition (EMT) has emerged as a key mechanism underlying resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC). However…
View article: Regional differences in epidermal growth factor receptor-tyrosine kinase inhibitor therapy in lung cancer treatment using a national database in Japan
Regional differences in epidermal growth factor receptor-tyrosine kinase inhibitor therapy in lung cancer treatment using a national database in Japan Open
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are extensively used in the treatment of non-small cell lung cancer (NSCLC); hence, equal access to them is important. Therefore, this study aimed to identify regional…
View article: Adverse events induced by durvalumab and tremelimumab combination regimens: a systematic review and meta-analysis
Adverse events induced by durvalumab and tremelimumab combination regimens: a systematic review and meta-analysis Open
Background: Immune checkpoint inhibitors (ICIs) have shown remarkable therapeutic outcomes among cancer patients. Durvalumab plus tremelimumab (DT) is under investigation as a new ICI combination therapy, and its efficacy has been reported…
View article: Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non‐small‐cell lung cancer: A multicenter retrospective trial
Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non‐small‐cell lung cancer: A multicenter retrospective trial Open
Background Pembrolizumab alone or in combination with chemotherapy is a standard treatment for patients with non‐small‐cell lung cancer (NSCLC) with high programmed death‐ligand 1 (PD‐L1) expression. However, no study has compared the effi…
View article: P8‐55: A review of cases of gene panel testing using next‐generation sequencers at our hospital
P8‐55: A review of cases of gene panel testing using next‐generation sequencers at our hospital Open
therefore probable candidates for ICIs.
View article: P8‐81: Concurrent chemoradiotherapy with cisplatin + S‐1 versus cisplatin + other third‐generation agents for locally advanced non‐small‐cell lung cancer: A meta‐analysis of individual patient data
P8‐81: Concurrent chemoradiotherapy with cisplatin + S‐1 versus cisplatin + other third‐generation agents for locally advanced non‐small‐cell lung cancer: A meta‐analysis of individual patient data Open
malignant nodules ( AUC 0.638 (P = 0.025), AUC 0.646 (P = 0.021), AUC 0.655 (P = 0.013), respectively).In conclusion, this study shows that there is no significant difference between the three mathematical models in predicting malignancy i…
View article: P8‐80: Bevacizumab suppresses epithelial‐to‐mesenchymal transition in EGFR‐mutant lung cancer
P8‐80: Bevacizumab suppresses epithelial‐to‐mesenchymal transition in EGFR‐mutant lung cancer Open
malignant nodules ( AUC 0.638 (P = 0.025), AUC 0.646 (P = 0.021), AUC 0.655 (P = 0.013), respectively).In conclusion, this study shows that there is no significant difference between the three mathematical models in predicting malignancy i…
View article: P8‐54: Is combination chemotherapy with ICI and cytotoxic agents always better than monotherapy with ICI in patients with advanced NSCLC?
P8‐54: Is combination chemotherapy with ICI and cytotoxic agents always better than monotherapy with ICI in patients with advanced NSCLC? Open
therefore probable candidates for ICIs.
View article: P8‐154: Pulmonary epithelioid hemangioendothelioma in adult young man
P8‐154: Pulmonary epithelioid hemangioendothelioma in adult young man Open
Background and Aims: Bronchoscopic techniques like endobronchial ultrasound (EBUS) and EUS-B (endoscopic ultrasound with bronchoscope) has a key role in diagnosing and or staging mediastinal and central lesions of the lung.EBUS is still in…
View article: A functionally improved case of obstructive impairment caused by systemic lupus erythematosus
A functionally improved case of obstructive impairment caused by systemic lupus erythematosus Open
Pulmonary lymphoproliferative diseases are often associated with collagen diseases. In addition to treatment of the primary disease, additional treatments may be considered depending on the pathology presented in the case. https://bit.ly/3…
View article: T‐cell response to phytohemagglutinin in the interferon‐γ release assay as a potential biomarker for the response to immune checkpoint inhibitors in patients with non‐small cell lung cancer
T‐cell response to phytohemagglutinin in the interferon‐γ release assay as a potential biomarker for the response to immune checkpoint inhibitors in patients with non‐small cell lung cancer Open
Background Immune checkpoint inhibitors are a standard treatment for advanced lung cancer, although it remains important to identify biomarkers that can accurately predict treatment response. Immune checkpoint inhibitors enhance the antitu…
View article: Resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer patients: A meta‐analysis
Resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer patients: A meta‐analysis Open
Background Differences in the resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in patients with non‐small cell lung cancer (NSCLC) harboring epidermal growth factor receptor mutations are unknown. This m…
View article: <scp>MicroRNA</scp>‐200b is a potential biomarker of the expression of <scp>PD‐L1</scp> in patients with lung cancer
<span>MicroRNA</span>‐200b is a potential biomarker of the expression of <span>PD‐L1</span> in patients with lung cancer Open
Background Advanced non‐small cell lung cancer (NSCLC) has a high mortality rate and poor prognosis. However, outcomes have gradually improved after the introduction of novel immunotherapies, including immune checkpoint inhibitors (ICIs). …
View article: Identification of Biomarkers for Non–small-cell Lung Cancer Patients Treated With an Immune Checkpoint Inhibitor
Identification of Biomarkers for Non–small-cell Lung Cancer Patients Treated With an Immune Checkpoint Inhibitor Open
A high level of post-ANCs was associated with poor outcome in ICI-treated NSCLC patients.
View article: Afatinib + bevacizumab combination therapy in <scp><i>EGFR</i></scp>‐mutant <scp>NSCLC</scp> patients with osimertinib resistance: Protocol of an <scp>open‐label</scp>, phase <scp>II</scp>, multicenter, <scp>single‐arm</scp> trial
Afatinib + bevacizumab combination therapy in <span><i>EGFR</i></span>‐mutant <span>NSCLC</span> patients with osimertinib resistance: Protocol of an <span>open‐label</span>, phase <span>II</span>, multicenter, <span>single‐arm</span> trial Open
Introduction As most patients with epidermal growth factor receptor ( EGFR )‐mutant non‐small cell lung cancer (NSCLC) develop progressive disease after treatment with osimertinib, it is important to develop more effective treatment option…
View article: Identification of Predictive Biomarkers for Immunotherapy with Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer
Identification of Predictive Biomarkers for Immunotherapy with Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer Open
View article: Effects of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors on Immune Checkpoints
Effects of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors on Immune Checkpoints Open
View article: Class A CpG oligodeoxynucleotide inhibits IFN‐γ‐induced signaling and apoptosis in lung cancer
Class A CpG oligodeoxynucleotide inhibits IFN‐γ‐induced signaling and apoptosis in lung cancer Open
Background Currently, anticancer immunotherapy based on PD‐1/PD‐L1 blockade with immune checkpoint inhibitors (ICIs) is being used as a standard therapy for non‐small cell lung cancer (NSCLC). However, more effective treatments are require…
View article: ABSTRACT WITHDRAWN
ABSTRACT WITHDRAWN Open
A 42-year-old man with a 4-month history of retrosternal pain and a 2-month history of skin rashes and proximal muscle weakness was diagnosed with dermatomyositis (DM) based on muscle enzyme analysis and needle electromyography.Computed to…
View article: LONG NON‐CODING RNA GROWTH ARREST SPECIFIC‐5: A POTENTIAL BIOMARKER FOR DIAGNOSIS OF SEVERE ASTHMA
LONG NON‐CODING RNA GROWTH ARREST SPECIFIC‐5: A POTENTIAL BIOMARKER FOR DIAGNOSIS OF SEVERE ASTHMA Open
A 42-year-old man with a 4-month history of retrosternal pain and a 2-month history of skin rashes and proximal muscle weakness was diagnosed with dermatomyositis (DM) based on muscle enzyme analysis and needle electromyography.Computed to…